Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

@article{Khorashad2008FindingOK,
  title={Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.},
  author={Jamshid S Khorashad and Hugues de Lavallade and Jane F. Apperley and Dragana Milojkovic and Alistair G. Reid and Marco Bua and Richard M. Szydlo and Eduardo Olavarr{\'i}a and Jaspal Singh Kaeda and John M. Goldman and D. W. Marin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 29},
  pages={4806-13}
}
PURPOSE Kinase domain (KD) mutations in the BCR-ABL gene are associated with resistance to imatinib in chronic myeloid leukemia (CML) but their incidence and prognostic significance in chronic phase (CP) patients without resistance are unclear. PATIENTS AND METHODS We analyzed outcome for 319 patients with CML-CP who were treated with imatinib; 171 were in early CP (ECP) and 148 were in late CP (LCP). Patients were screened routinely for mutations using direct sequencing regardless of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 81 extracted citations

Chronic myeloid leukemia stem cells.

Hematology. American Society of Hematology. Education Program • 2008
View 7 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib

H Kantarjian, A Quintas-Cardama, S O’Brien
Blood 110:314a, • 2007

Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival

B Druker, F Guilhot, S O’Brien
N Engl J Med 355:2408-2417, • 2006

Similar Papers

Loading similar papers…